In the midst of negotiations, Pharma continues to push for the NHS to pay more for pharmaceuticals: we evaluate the economics behind 3 of their claims (1/5) lse.ac.uk/News/Latest-ne…

If you missed James Lomas at the York Festival of Ideas you can now watch his Panel Discussion here 👉youtu.be/Tm899kmxaE0

📢Are you a #Researcher with a keen interest in #ethics - particularly around developments in #bioscience and #medicine? We're on the lookout for TWO #Research & #Policy Managers to join our team. 🔗Find out more about these exciting NEW roles & apply: bit.ly/NB_jobs_RPMs_tw

Academia has driven me to drink. A glass of wine might not solve the total dung heap of a system that is academic publishing, but it’s certainly helping.

This one took a LOT of effort, was a long time coming and involved an incredible group of people. If you’re interested in healthcare priority setting or HTA, please do take a look. Available open access. cambridge.org/core/journals/…

It was a pleasure to be involved in this paper with this team and great to see it now in print! We need to talk about values in health tech assessment #prioritysetting #healtheconomics

Very pleased to see this paper published. Expertly led by Victoria Charlton and joined by 20+ co-authors, we set out to clarify the language used to articulate normative aspects of HTA. cambridge.org/core/journals/…

💊 It's time to talk about fair pharmaceutical pricing! 🤝 Join the conversation with Beth Woods, Keith Derbyshire, and Adrian Towse. Gain a better understanding of how pricing policies impact patients and innovation. Register today: shorturl.at/iGU12 #CHEPolicyForums

.Matthew A. Crane, MD, Tom Moore, and I examined online advertising by #ketamine clinics in MD and found several false and misleading claims. JAMA Network Open CU Pharmacy Johns Hopkins Bloomberg School of Public Health jamanetwork.com/journals/jaman…

If you want to join CaSE for 6 months as our Policy Intern, the deadline for applications is this Friday!

I was invited to write an editorial for the BMJ about NICE - difficult to get much within the 800 word limit! bmj.com/cgi/content/fu…

For those with an interest in clinical ethics and law, keen to learn more and mingle with like minded individuals. There is still time to book a place to attend! Info: ime-uk.org/events-and-new… #medicalethics #bioethics #medicallaw J. of Medical Ethics IME Postgrads

Love science? Enjoy sharing scientific content and ideas? Come study Science Communication at Imperial College London. I did and it was the best decision I ever made (many years ago). MSc application deadline 26 February. imperial.ac.uk/science-commun… #scicom #scipol

“Severity Weights” were introduced to NICE Methods in January 2022. TSD23 provides guidance on how severity shortfalls can be calculated, including the data sources that can be used in most appraisals. Find it here: shorturl.at/PQVX4

Can a healthcare priority-setter claim to be acting in a way that’s morally justified if its policy and/or practice are incoherent? We think not. Published today in J. of Medical Ethics , OA. Please read/ share (it’s nice and short!) #healthcare #ethics jme.bmj.com/content/early/…

If continuity of care was a drug with the same benefits and the NHS refused to provide it, there would be an outcry. But policymakers just treat it as an optional extra that never gets prioritised. Why won’t they learn? Wilful blindness? Ignorance? There’s really no excuse now.

Is NICE’s approach to healthcare priority setting morally justified? A complicated question but Mike DiStefano and I have used a novel systematic approach to try and answer it. Empirical bioethics in action. Open access. bmcmedethics.biomedcentral.com/articles/10.11…

Nice to see that our paper on alternative value measures was selected as a top paper in Expert Review of Pharmacoeconomics & Outcomes Research. Link below! Brett McQueen Kelly Anderson Kavita Nair

In a recent paper, we compared ICER's assessments of comparative effectiveness with added benefit ratings from the German Federal Joint Committee (G-BA). (1/9)